Topic desk · 4 reviewed briefs
Growth-hormone signaling peptides
Separate a measurable GH or IGF-1 response from muscle, fat-loss, recovery, and longevity outcomes.
Evidence boundary
Human pharmacology can be real while the promoted patient benefit remains untested or negative.
- Reviewed briefs
- 4
- Established contexts
- 1
- Reviewed claims
- 12
Before accepting a claim
Ask the question the promotion leaves out.
- 01
Was the study designed to measure a hormone response or a clinical outcome?
- 02
Which analogue, modification, and product was actually tested?
- 03
What do the current label and anti-doping rules say?
Connected briefs
Compare evidence without flattening it.
CJC-1295
A long-acting growth-hormone-releasing hormone analogue with clear human biomarker activity but no established clinical benefit for popular body-composition or recovery claims.
3 reviewed claims · Open brief ↗Ipamorelin
A growth-hormone secretagogue with demonstrated human pharmacology, a negative proof-of-concept efficacy trial, and unresolved route, safety, and product-quality questions.
3 reviewed claims · Open brief ↗Tesamorelin
An approved GHRF analogue for a specific HIV-associated body-composition outcome, not a general weight-loss or anti-aging medicine.
3 reviewed claims · Open brief ↗Sermorelin
A GHRH fragment with historical approvals and real hormone-release pharmacology, but no current approved product and no established anti-aging outcome evidence.
3 reviewed claims · Open brief ↗